A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy
NCT06742190
Recruiting
The main purpose of this study is to compare empasiprubart and IVIg in adult patients with MMN. The study consists of a double-blinded part A (empasiprubart, IVIg) and an open-label part B (empasiprubart). The maximum study duration for participants is up to 49 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/19/2025
Locations: HonorHealth Neurology - Bob Bove Neuroscience Institute - Neurology, Scottsdale, Arizona +18 locations
Conditions: Multifocal Motor Neuropathy (MMN), MMN
Register for Updates
Virtual Reality for Pain Management During Dupilumab Injection
NCT06182436
Recruiting
The aim of this within-subject randomized study is to examine the efficacy of a VR immersive game for pain and anxiety management of children during the subcutaneous injection of dupilumab for moderate to severe atopic dermatitis. We will recruit children from 6 to 17 years. The main research question is: 1. Does VR immersive game will generate less anxiety and pain than standard procedures, for children receiving dupilumab injection for moderate to severe atopic dermatitis? 2. Does the occure... Read More
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
08/18/2025
Locations: St. Justine's Hospital, Montréal, Quebec +1 locations
Conditions: Atopic Dermatitis, Pain, Anxiety
Register for Updates
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752
Recruiting
The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+), well differentiated Grade1 and Grade 2 (G1 and G2) (Ki-67 \<10%) advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with high disease burden
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
08/18/2025
Locations: Highlands Oncology Group, Fayetteville, Arkansas +13 locations
Conditions: Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Register for Updates
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT06290141
Recruiting
The purpose of the study is to evaluate efficacy of riliprubart compared to IVIg in adult participants with CIDP who are receiving maintenance treatment with IVIg. The study duration will be for a maximum of 109 weeks including screening, treatment phases, and follow-up.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Alabama Neurology Associates- Site Number : 8400019, Homewood, Alabama +89 locations
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Register for Updates
A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors
NCT06537310
Recruiting
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary clinical activity of RO7567132 as single agent and in combination with atezolizumab. The study will enroll adult participants with selected locally advanced and/or metastatic solid tumors for whom standard therapy does not exist, or has proven to be ineffective or intolerable.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Brown University Health, Providence, Rhode Island +15 locations
Conditions: Cancer-Neoplasms
Register for Updates
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
NCT07090330
Recruiting
This is a multicenter, randomized, double-blinded, placebo-controlled, proof-of-concept study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Oruka Therapeutics Investigative Site, Fountain Valley, California +15 locations
Conditions: Plaque Psoriasis
Register for Updates
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
NCT06581432
Recruiting
This is a study for people with advanced cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with HER2 alterations can join the study. The purpose of this study is to find out whether a medicine called zongertinib helps people with advanced cancers with HER2 alterations. HER2 alterations can cause cancer. Zongertinib inhibits HER2. Participants are put into 13 groups based on the type of advanced cancer and the type of HER2 alterations they have.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Alaska Oncology and Hematology, LLC, Anchorage, Alaska +66 locations
Conditions: Solid Tumours
Register for Updates
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
NCT07136012
Recruiting
The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp\[a\]).
Gender:
ALL
Ages:
Between 50 years and 105 years
Trial Updated:
08/18/2025
Locations: Advanced Cardiovascular LLC, Alexander City, Alabama +55 locations
Conditions: Cardiovascular Disease
Register for Updates
IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack
NCT06139328
Recruiting
This study is open to adults aged 18 and over who have just had a heart attack. The purpose of this study is to find out whether a medicine called BI 765845 helps people who have had a heart attack. The investigators also want to test how well different doses of BI 765845 work and how they are tolerated by people who have had a heart attack. Participants are randomly assigned to receive either BI 765845 or placebo. Placebo treatments look like BI 765845 treatments but do not contain any medicin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: University of Arizona, Tucson, Arizona +103 locations
Conditions: Myocardial Infarction
Register for Updates
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
NCT06408935
Recruiting
The purpose of this study is to evaluate the efficacy of guselkumab in healing of all layers of the digestive tract (transmural healing) with the help of a score called Magnetic Resonance Index of Activity (MaRIA) based on a scan at Week 48.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Center for Colitis and Crohns Disease University of California, San Francisco, California +72 locations
Conditions: Crohn's Disease
Register for Updates
Virtual Reality Distraction for Dental Anxiety (RCT)
NCT06182462
Recruiting
The aim of this randomized clinical trial is to verify the efficacy of VR immersion over a muted cartoon on a wall-mounted TV to decrease dental fear and anxiety of children undergoing dental procedures. The study also aims to gain insight on the satisfaction of parents and healthcare providers on the use of VR during dental appointments. Main research question: Does VR immersion compare to a cartoon on a wall-mounted TV is more efficacious to decrease dental fear and anxiety of children requir... Read More
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
08/18/2025
Locations: St.Justine's Hospital, Montreal, Quebec
Conditions: Dental Anxiety, Dental Phobia, Dental Trauma, Dental Diseases
Register for Updates
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
NCT06467357
Recruiting
The purpose of this study is to measure the efficacy and safety of T-DXd with rilvegostomig or T-DXd monotherapy compared with gemcitabine plus cisplatin and durvalumab in patients with advanced treatment naïve HER2-expressing BTC.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/18/2025
Locations: Research Site, Scottsdale, Arizona +254 locations
Conditions: Biliary Tract Cancer
Register for Updates